10 December 2012

Preliminary Results from an Early Phase Trial of Gene Engineered T Cells Targeting Cancer Testis Antigens in Multiple Myeloma

(Atlanta, GA and Oxford, UK) 10 December, 2012.  Adaptimmune today announces the release of preliminary results from an early phase clinical study using patients’ own T cells that have been genetically altered to attack multiple myeloma (MM) cells.  Lead investigators for the study presented today in three separate sessions at the annual meeting of the American Society of Hematology (ASH).

Please click here for full Press Release

« Back to News